Methods of inhibiting ire1

TL;DR: In this paper, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1 or Src.

TL;DR: In this article, a list of compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof are presented, which can be used as single agents or in combination therapies.

TL;DR: In this article, novel therapeutic compounds and methods of using the same for the treatment of cancers are presented and methods for using these compounds for cancer treatment are described and discussed. But none of these methods are suitable for breast cancer patients.

TL;DR: In this article, fused ring heteroaryl compounds useful in a variety of methods, including reducing the activity of certain kinases and treating certain disease states, are presented, and compared.

TL;DR: In this article, the authors describe a class of liponucleotides containing an ether linkage in the 2-position and a thioether, sulfoxide, or sulfone linkage in 3-position.

TL;DR: A benzimidazole derivative represented by the general formula [I]: [I] wherein R1 and R2 each independently represent lower alkyl, etc; R3 represents hydrogen, etc.; B1, B2, and B3 each represents hydrogen or lower alyl; W represents a bond, -(CH2)-CONH-(CH2), etc; Ar1 represents a 5- or 6-membered aromatic nitrogenous heterocyclic group optionally containing oxygen or sulfur; and Ar2 represents optionally substituted, mono- or bicyclic, aromatic carb

TL;DR: In this paper, the authors present novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity, which are of Formula (I):

TL;DR: In this paper, the A2A receptor activation of the adenosine A 2A receptor has been studied and a process for preparing the compounds is described, as well as pharmaceutical compositions that contain the compounds.